Please assess the completion status of the following clinical trial:

Trial Title: An Open-label Study Assessing Safety, Immunogenicity and Dose Response of IC84

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~1. Healthy adults ≥18 years of age.~2. No clinically relevant pathological findings in any of the investigations at the Screening Visit including subjects with pharmacologically controlled conditions like hypercholesterolemia, hypertension, cardiovascular disease or non insulin-dependent diabetes mellitus. Minor deviations of laboratory values from the normal range may be accepted, if judged by the investigator to have no clinical relevance.~3. In female subjects, either childbearing potential terminated by surgery or 1 year post menopausal, or a negative serum pregnancy test during screening and the willingness not to become pregnant during the entire study period by practicing reliable methods of contraception.~4. Weight: ≥ 45.5 kg and \<= 150 kg at Visit 0 (Screening Visit).~5. White blood cells ≥2,500/mm3 and \<11,000/mm3 at Visit 0.~6. Platelets within normal limits at Visit 0.~7. Written informed consent obtained from the subject prior to any study related procedures.~Exclusion Criteria:~1. Use of any other investigational or non-registered medicinal product within 30 days prior to IC84 vaccination at Visit 1 (Day 0) and throughout the entire study period.~2. Active or passive vaccination four weeks before first vaccination at Visit 1 and during the entire study period.~3. Immunodeficiency including status post-organ-transplantation or immuno-suppressive therapy, and a family history of congenital or hereditary immunodeficiency.~4. Infection with the human immunodeficiency virus (HIV, a negative test result within 30 days before screening is acceptable), Hepatitis B virus (HBV, Hepatitis B surface antigen \[HBsAg\]) or Hepatitis C virus (HCV).~5. History of severe hypersensitivity reactions and anaphylaxis.~6. History of allergic bronchial asthma and severe allergic rhinoconjunctivitis.~7. Known hypersensitivity or allergic reactions to one of the components of the vaccine.~8. History of autoimmune disease, including Type I Diabetes mellitus. Subjects with vitiligo or thyroid disease taking thyroid hormone replacement are not excluded.~9. Any malignancy in the past 5 years. If treatment for cancer was successfully completed more than 5 years ago and the malignancy is considered to be cured, the subject may be enrolled.~10. Clinically significant hematological, renal, hepatic, pulmonary, central nervous, cardiovascular or gastrointestinal disorders, which are not adequately controlled by medical treatment within the last 12 weeks before IC84 vaccination at Visit 1 (Day 0) as judged by the site's Principal Investigator.~11. Systemic antibiotic use within four weeks prior to first vaccination and during treatment period (until Day 28).~12. Clinically significant diseases as judged by the investigator.~13. Administration of chronic (defined as longer than 14 days) immunosuppressants or other immune-modifying drugs within 30 days prior to IC84 vaccination at Visit 1 (Day 0) and during the study until Visit 5 (Day 28). (For corticosteroids this means prednisone or equivalent \>= 0.05 mg/kg/day; topical and inhaled steroids are allowed.).~14. Periodic steroid injections, e.g., intra-articular, are not allowed within 30 days prior to first IC84 vaccination at Visit 1 (Day 0) and until Visit 5 (Day 28).~15. Intake of NSAID within three days prior to and within three days after all three vaccinations (Day 0, 7 and 21).~16. Acute febrile infections or exacerbation of chronic infection within four weeks prior to first vaccination at Visit 1 and during treatment period (until Day 21).~17. Body temperature \> 37°C (oral) immediately prior to each vaccination.~18. Drug addiction within 6 months prior to Visit 0 \[including alcohol dependence, i.e. more than approximately 60 g alcohol (approximately 1 liter of beer or 0.5 liter of wine) per day\] indicated by an elevated MCV above normal value at the Screening Visit.~19. Inability or unwillingness to avoid more than the usual intake of alcohol \[i.e., not more then 60 g alcohol (approximately 1 liter of beer or 0.5 liter of wine) per day\] during the 48 hours after vaccination.~20. Pregnancy (positive pregnancy test during screening), lactation or unreliable contraception in female subjects with child-bearing potential ( and unreliable contraception in male subjects.~21. Not able to understand and comply with protocol requirements, instructions and protocol-stated restrictions.~22. Blood donation within 4 weeks prior to first vaccination.~23. Clinically significant mental disorder not adequately controlled by medical treatment.~24. History of Guillain-Barré-Syndrome (GBS).~25. Any condition which might interfere with study objectives or would limit the subject's ability to complete the study in the opinion of the investigator.~26. Inability or unwillingness to provide informed consent.~27. Persons who are committed to an institution (by virtue of an order issued either by the judicial or the administrative authorities).

- Gender: ALL
- Minimum Age: 65 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- IC84, 75 µg w/ Alum (Type: EXPERIMENTAL): 75 µg w/ Alum (microgram with Alum)
- IC84, 75 µg w/o Alum (Type: EXPERIMENTAL): 75 µg w/o Alum (microgram without Alum)
- IC84, 200 µg w/ Alum (Type: EXPERIMENTAL): 200 µg w/ Alum (microgram with Alum)
- IC84, 200 µg w/o Alum (Type: EXPERIMENTAL): 200 µg w/o Alum (microgram without Alum)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete